Researchers find tirzepatide more effective than semaglutide for weight loss in a 72-week trial, with significant reductions ...

A new clinical trial has revealed that tirzepatide (Zepbound) surpasses semaglutide (Wegovy) in promoting weight loss among ...

Women typically lose more weight on Zepbound and Wegovy than men do ... want to consider detailed results on how the two medicines compare across different types of patients before making ...

Early-stage study results suggest that a single shot of the company’s therapy, which works differently than GLP-1 medicines, ...

though 6.1% of those in the Zepbound arm discontinued treatment due to adverse events. By comparison, 8.0% of participants the Wegovy arm discontinued treatment. Lilly added that the study was not ...

according to detailed results from a direct comparison trial published in The New England Journal of Medicine. On average, those taking Zepbound lost 50.3 pounds, while those on Wegovy lost 33.1 ...

During the trial, 6.1% of participants taking Zepbound discontinued treatment due to adverse events, compared to 8.0% of participants taking Wegovy. However, the study was not powered to compare ...

During the trial, 6.1% of participants taking Zepbound discontinued treatment due to adverse events, compared to 8.0% of participants taking Wegovy. However, the study was not powered to compare ...

"This study allowed us to do a direct comparison." "The results are ... clinical trial programs and in SURMOUNT-5, both Wegovy and Zepbound have demonstrated clinically significant weight ...